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Medical University of Gdanśk, Gdanśk, Poland, 6 San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Division of 
Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, 7 MRC Centre for 
Transplantation, King’s College London, London, United Kingdom
Adoptive therapy with regulatory T cells or tolerance-inducing antigen (Ag)-presenting 
cells is innovative and promising therapeutic approach to control undesired and harmful 
activation of the immune system, as observed in autoimmune diseases, solid organ and 
bone marrow transplantation. One of the critical issues to elucidate the mechanisms 
responsible for success or failure of these therapies and define the specificity of the 
therapy is the evaluation of the Ag-specific T-cell responses. Several efforts have been 
made to develop suitable and reproducible assays. Here, we focus on dye-based prolif-
eration assays. We highlight with practical examples the fundamental issues to take into 
consideration for implementation of an effective and sensitive dye-based proliferation 
assay to monitor Ag-specific responses in patients. The most critical points were used to 
design a road map to set up and analyze the optimal assay to assess Ag-specific T-cell 
responses in patients undergoing different treatments. This is the first step to optimize 
monitoring of tolerance induction, allowing comparison of outcomes of different clinical 
studies. The road map can also be applied to other therapeutic interventions, not limited 
to tolerance induction therapies, in which Ag-specific T-cell responses are relevant such 
as vaccination approaches and cancer immunotherapy.
Keywords: tolerance, monitoring, proliferation, antigen-specific, t cells, transplantation, autoimmune diseases, 
immune-therapies
INtroDUctIoN
The induction of antigen (Ag)-specific tolerance in transplanted or autoimmune disease patients is 
a pre-eminent goal in precision medicine. Progressively, several tolerance-inducing strategies are 
entering the clinical arena with immune-modulatory drugs, including novel therapeutic antibodies 
(1, 2) and cell therapies with regulatory T cells (Tregs) or tolerogenic Ag-presenting cells (tolAPCs). 
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Hence, the need for in vitro assays to evaluate the immunological 
mechanisms responsible for failure or success of these therapies 
is becoming critical. It may discriminate Ag-specific tolerance 
induction from general immune suppression and potential 
loss of pathogen-specific immunity. In addition, assessment of 
Ag-specific memory for tolerance may allow identification of 
patients in whom tapering of immunosuppression is likely to be 
safe, thus minimizing risks of adverse effects resulting from the 
ongoing treatments.
To evaluate Ag-specific responses in  vitro, peripheral blood 
mononuclear cells (PBMCs) are the most widely used cells due 
to their relative convenient accessibility. Various methods to 
monitor Ag-specific responses have been developed, including 
measurement of cytokine production of Ag-responding T cells 
with enzyme-linked immunosorbent assay (ELISA) or enzyme-
linked immunospots (ELISpots), or analysis of T-cell proliferation 
based on 3H-thymidine incorporation. Technical developments 
in the field of flow cytometry opened new possibilities for 
analysis and characterization of cell sub-populations and their 
Ag-specific responses using fluorescent dye dilution (3, 4) and 
flow cytometric assay of specific cell-mediated immune response 
in activated whole blood (FASCIA) (5, 6). Cell permeant dyes, 
such as carboxyfluorescein diacetate succinimidyl ester (CFSE), 
cell trace violet (CTV), and violet proliferation dye 450 (VPD-
450), enabled more specific analysis of cell proliferation over 
several days. Since the dyes are divided equally between daughter 
cells (7), the number of cell divisions of the proliferating cells 
can be visualized, thus allowing the theoretical enumeration of 
Ag-specific cells. Moreover, dividing cells can phenotypically be 
characterized using antibodies specific for surface markers and/
or intracellular cytokines (8). This multiplies the information 
to be obtained from a single functional assay. It still remains to 
be defined, however, whether analysis with proliferation dyes 
is sensitive enough to evaluate the induction of tolerance in 
transplantation settings and autoimmunity, where the numbers 
of autoAg-specific cells are generally very low (9, 10).
Only recently, the use of dye proliferation to monitor 
Ag-specific T-cell responses has been introduced in clinical prac-
tice. Responsiveness to insulin in a small number of children in 
randomized clinical study, Pre-POINT study, demonstrated the 
value of combining proliferation dye with analysis for specific T 
helper profiles. The analysis demonstrated that the observed insu-
lin- and pro-insulin-specific proliferating CD4+ T cells acquired 
a Treg phenotype (11). Similarly, Ag-specific T-cell proliferation 
in response to Derp1 in small cohort of patients undergoing dust 
mite allergen-specific immunotherapy was used to demonstrate 
the ability of the treatment to promote unresponsiveness in 
allergen-specific T helper cells (12). These studies highlight the 
limitation of applying dye proliferation assay, as T-cell responses 
could only be evaluated in a fraction of treated patients. However, 
these examples also indicate that dye proliferation assay can be a 
valuable tool to better dissect the effect of a given therapy, since 
in combination with gene profile or phenotypical analysis (i.e., 
FOXP3 expression or intracytoplasmic staining for cytokines) 
can help to grasp the mechanism underlying tolerance induction.
Studies correlating transplant outcome with in vitro functional 
studies have been mostly non-conclusive [as reviewed in Ref. 
(13)]. In a trial of allo-specific tolerance induction, however, 
an absence of proliferation to the donor was observed in those 
patients that could continue with immunosuppression withdrawal 
(14). Besides in a study focused on finding a biomarker signature 
to detect renal transplant tolerance in humans the comparison of 
in  vitro T-cell function between spontaneously tolerant kidney 
transplant recipients and non-tolerant recipients demonstrated 
that the best correlation to the clinical status was obtained with 
donor-specific IFNγ-ELISpot assays (15).
With the aim to join forces in development and implemen-
tation of tolerance-inducing cell products, such as Tregs and 
tolAPCs, a European network action to focus and accelerate 
cell-based tolerance-inducing therapies (A FACTT, www.
afactt.eu) was initiated in 2014 under the umbrella of European 
Cooperation in Science and Technology (COST). By creating 
a forum for the exchange and integration of knowledge and 
expertise, A FACTT aims to minimize overlap and maximize 
comparison of the diverse tolerance-inducing cell products, but 
also to create consensus on monitoring parameters, immune-
monitoring assays and establish minimum information models 
(16–18). Therefore, within A FACTT, we have determined the 
critical steps of a dye-based proliferation assay to monitor 
Ag-specific T-cell responses useful for assessing the results of 
tolerance-inducting therapies, since assay harmonization to 
monitor tolerance induction is essential to compare outcomes 
of different clinical studies.
In the current study, we propose a road map for the execution 
and analysis of dye-based proliferation assays for high-sensitivity 
monitoring of T-cell responses specific for alloAgs, pathogen-
derived exogenous Ags, and autoAgs. This approach will be of 
pivotal importance for defining effects of tolerance-inducing 
strategies for transplantation and autoimmune diseases.
MAtErIAls AND EQUIPMENt
subjects
Human peripheral blood was obtained from healthy donors upon 
informed consent in accordance with local ethical committee 
approval and with the Declaration of Helsinki.
Human peripheral blood was obtained from four multiple 
sclerosis (MS) patients from the Multiple Sclerosis Unit, Germans 
Trias I Pujol University Hospital (Badalona, Spain) upon 
Abbreviations: A FACTT, a European network action to focus and accelerate cell-
based tolerance-inducing therapies; Ag, antigen; allo, allogeneic; APC, antigen-
presenting cell; auto, autologous; CFSE, carboxyfluorescein diacetate succinimidyl 
ester; cpm, counts per minute; COST, European Cooperation in Science and 
Technology; CTV, cell trace violet; DC, dendritic cell; DI, division index; ELISA, 
enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot; 
FASCIA, flow cytometric assay of specific cell-mediated immune response in 
activated whole blood; FBS, fetal bovine serum; GAD, glutamic acid decarboxylase; 
HS, human serum; OVA, ovalbumin; mAb, monoclonal antibody; MBP, myelin 
basic protein; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; 
PBMCs, peripheral blood mononuclear cells; Pen/strep, penicillin-streptomycin; 
PF, precursor frequency; PI, proliferation index; PLP, proteolipid protein; SEB, 
Staphylococcal enterotoxin B; SI, stimulation index; Tregs, regulatory T  cells; 
tolAPCs, tolerogenic antigen-presenting cells; tolDC, tolerogenic dendritic cells; 
T1D, type 1 diabetes; VPD-450, violet proliferation dye 450.
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informed consent in accordance with local ethical committee 
approval and with the Declaration of Helsinki. No patient had 
clinical exacerbations or was receiving corticosteroid or disease 
modifying treatments at the moment of the sample collection.
cell Preparations
Peripheral blood mononuclear cells were isolated from buffy 
coats obtained from healthy volunteer blood donor by Ficoll-
Uropoline, Ficoll-Hypaque, or Lymphoprep gradient centrifuga-
tion and were either used fresh or after storing them in liquid 
nitrogen. CD4+ T  cells were separated by negative selection 
(StemCell Technologies or Miltenyi Biotec) according to manu-
facturer’s instructions, with a resulting purity of >95%. Dendritic 
cells and CD3-depleted PBMC were prepared as previously 
described (19, 20).
Dye-labeling and Proliferation
Polyclonal Stimulation
Responder cells were washed twice with warm (37°C) PBS to 
remove serum that affects staining. Then, cells were suspended 
in warm (37°C) PBS at a concentration of 5 × 106 cells/ml and 
labeled with various concentrations of CFSE (Invitrogen, 
USA) or VPD-450 (BD Biosciences, USA) at 37°C for 15 min. 
Each 5 min cells were vortexed to provide uniform staining. 
Subsequently, cells were washed with warm (37°C) PBS and 
then with culture medium (X-VIVO 20; Lonza) supplemented 
with 10% fetal bovine serum (FBS) and antibiotics pen/strep. 
After this step, cells were suspended in fresh medium (X-VIVO 
20, 10% FBS, pen/strep) and incubated for 24 h. After this time, 
the labeled cells were collected, washed with fresh medium, 
counted, seeded on 96-well plates (1  ×  105 cells/well), and 
stimulated with magnetic beads coated with anti-CD3 and 
anti-CD28 antibodies (Invitrogen) in 1:1 cell:bead ratio. 
In parallel, stained and not stimulated cells, as well as unstained 
and stimulated cells, were seeded in the same concentration 
as controls. After 96 h, cells were collected and stained with 
7-AAD (20 min, at RT). Sample of unlabeled and stimulated 
cells was stained with anti-CD45 V450 mAb (BD Horizon, 
USA) or with anti-CD45-FITC mAb (BD Biosciences). After 
viability check, one well of CSFE or VPD-450 stained stimu-
lated cells was mixed with one well of stained unstimulated 
cells and one well of unstained stimulated cells labeled with 
anti-CD45 V450 mAb or with anti-CD45 FITC mAb when 
CFSE or VPD-450 was used, respectively. Immediately after 
this step, cells were analyzed with flow cytometer (LSRFortessa; 
BD Biosciences).
Staphylococcal Enterotoxin B (SEB) Stimulation
Thawed PBMCs (10 × 106 cells/ml) were incubated with 2 µM of 
VPD-450 (BD Biosciences) for 7 min at RT in the dark. Afterward, 
cells were washed twice with medium and resuspended in IMDM 
5% human serum (HS) (Sanquin), pen/strep at a concentra-
tion of 1 × 106 cells/ml, plated in 24-well plate, and stimulated 
with 1 µg/ml SEB (Sigma Aldrich). After 4 or 5 days, cells were 
harvested, washed with PBS, and stained with near-IR dead cell 
stain (Thermo Fischer Scientific Inc.) for 30  min at RT in the 
dark. Subsequently, cells were stained with anti-CD3-BUV496, 
anti-CD4-Ag-presenting cell (APC), and anti-CD8-BUV805 
(BD Biosciences, USA) and analyzed with flow cytometer 
(LSRFortessa; BD Biosciences). Data were analyzed using the 
FlowJo software (V10).
AlloAg and Pathogen-Specific Ag Stimulation
Fresh PBMCs and purified CD4+ T cells were labeled eFluor® 670 
(10 µM) (eBioscience) and incubated for 10 min at 37°C in the 
dark. The labeling of cells was stopped by adding 4–5 volumes 
of cold FBS (Lonza) and incubating the cells on ice for 5 min. 
Then, cells were washed and resuspended in culture medium: 
X-VIVO15 medium with 5% HS (BioWhittaker-Lonza), pen/
strep (BioWhittaker). To evaluate the allo-specific proliferative 
response, labeled PBMCs or CD4+ T cells were used as responder 
cells (R, 105 cells/well). As stimulators (S), either autologous 
(auto)/allogeneic (allo) CD3-depleted PBMCs (APC) at [R:S] 
ratio of [1:1] or auto/allo mature dendritic cell (mDC) at a [10:1] 
ratio were used. Cells were cultured for 4–6  days in 200  µl of 
X-vivo 5% HS in 96-well round-bottom plates. To evaluate the 
Ag-specific proliferative response labeled PBMCs (2 × 105 cells/
well) were plated in 96-well flat-bottom plates and stimulated 
either with heat-inactivated Candida albicans spores (5 ×  106 
spores/well, kindly provided by L. Romani, University of Perugia) 
or with tetanus toxoid (5 µg/ml; Enzo Life Sciences), or with total 
protein extract from a cell line infected with Varicella zoster Virus 
(2.5  µg/ml; Advanced Biotech) in a final volume of 200  µl of 
X-vivo (BioWhittaker-Lonza) 5% HS. For live/dead cell discrimi-
nation, PBMC or CD4+ T cells were stained with Pacific Blue™ 
Succinimidyl Ester (ThermoFisher) at a final concentration of 
0.1 µg/ml, according to manufacturer’s instructions. Proliferated 
cells were counterstained with anti-CD3 Pacific Orange (clone 
UCHT1), anti-CD4 Pecy7 (clone SK3, BD Bioscience), and 
anti-CD8 APC-Cy7 (clone SK1, BD) mAbs by 15 min incubation 
at RT in PBS 2% FBS. Cells were washed with PBS 2% FBS and 
fixed with 0.25% formaldehyde. Flow cytometry analyses were 
performed with FCS Express 4 [De Novo Software; (https://www.
denovosoftware.com/site/manual/proliferation_statistics.htm)], 
and the frequency of precursors was calculated according to the 
automatic proliferation fit statistics, as described in the manufac-
turer’s instructions. Alternatively, after 3, 4, or 5 days, cells were 
pulsed for 16 h with 1 μCi/well 3H-thymidine.
AutoAg Stimulation
Fresh PBMCs were labeled with VPD-450 (BD Horizon). A total 
of 8 ×  106 cells/ml were stained with 1  µM VPD-450, 14  min 
at 37°C, in dark. After two washing steps with PBS, cells were 
resuspended in 1  ml of RPMI (Sigma-Aldrich) supplemented 
with 10% FBS, pen/strep (Cepa and Normon, respectively) and 
2 mM l-glutamine (Sigma-Aldrich). A total of 1.5 × 105 PBMCs 
in 200 µl/well (5 wells/patient) were cultured in 96-well round-
bottom plates for 7 days at 37°C in the presence of 5 µM of 7 myelin 
peptides [myelin oligodendrocyte glycoprotein (MOG) 1–20, 
MOG35–55, PLP139–154, myelin basic protein (MBP) 13–32, 
MBP83–99, MBP111–129 and MBP146–170]. Non-stimulated 
PBMC and 25  ng/ml phorbol 12-myristate-13-acetate (PMA) 
plus 250  ng/ml Ionomycin (Sigma-Aldrich) stimulated blood 
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sample were used as negative and positive control, respectively. 
After 7  days of culture, PBMCs were stained with CD3-V500 
(BD Horizon), CD45-APC, 7-AAD (actinomycin D), and CD4-
FITC/CD8-PE (BD Biosciences), acquired with FACS Canto 
II (BD Bioscience) and analyzed using the FlowJo software. 
Alternatively, to analyze cell proliferation using 3H-thymidine 
incorporation, after 7 days of cell culture (1.5 × 105 PBMCs/well, 
60 wells/patient) with myelin peptides, cells were pulsed for 18 h 
with 1 μCi/well 3H-thymidine.
ovalbumin (oVA) stimulation for 
Frequency calculation
Responder Cells
BALB/C mice were purchased from Harlan (UK) and DO11.10 
naive mice were bred in house and maintained in pathogen-
free facilities (mice care was in accordance with institutional 
guidelines). Naive CD4+ T cells were isolated from splenocytes 
and peripheral lymph node lymphocytes by incubation with 
MoAbs: CD8 (56-3.72) and MHC class II (MS/114.15-2), locally 
produced hybridomas, CD16/32 and B220 (Becton Dickinson 
BD-Pharmingen), and CD25 (BD-Pharmingen), followed by 
negative selection using magnetic beads coated with sheep-anti 
rat IgG antibody (Dynal). Efficacy of depletion was measured by 
flow cytometry, and in all cases, CD4+ fractions were >85% pure; 
for DO11.10, the MoAb KJ126 (Caltag) was used. Cell calcula-
tions in our population were adjusted using this percentage.
Stimulator Cells
CHO cells doubly transfected with mouse CD86 and H-2Ad 
were used as stimulators. CHO cells were maintained in cul-
ture as previously described (21), and prior to culture, they 
were incubated with 30 µg/ml Mitomycin C (Kiowa) for 1 h at 
37°C, extensively washed and irradiated at 100 Gy. These cells 
were used to present OVA peptide 323–339 (Sigma) in the 
context of H-2Ad. All experiments with murine samples were 
performed in RPMI 1640 (Sigma) supplemented with pen/strep 
(Gibco), l-Glutamine 2 mM (Gibco), 10 mM HEPES (Gibco), 
2β-mercaptoethanol (Gibco), and 10% fetal calf serum (SeraQ).
CFSE Labeling for Frequency Calculation
BALB/C and DO11.10 CD4 T cells were labeled independently 
with CFSE (Molecular Probes, Leiden, The Netherlands) as fol-
lows: 2 × 107 cells were incubated with 1 µM of CFSE for 3 min at 
RT, washed extensively and were left overnight at 37°C 5% CO2 in 
culture medium. Known numbers of DO11.10 cells into BALB/C 
were mixed as above and incubated for 96 h at 37°C, 5% CO2 with 
stimulator cells and 0.5 µg/ml OVA323–339 peptide. Cells incubated 
in the absence of peptide were used as negative controls. Cells 
stimulated with 200  pg/ml phorbol dibutyrate (Sigma) and 
1 µM Ionomycin (Sigma) were used as positive controls. Before 
acquisition in the flow cytometer, cells were labeled with mouse 
CD4-APC (Caltag), the clonotypic marker KJ126-PE (Caltag), 
and 20 ng/ml of propidium iodide (Sigma), thus enabling gating 
of the clonotypic receptor-expressing live CD4+ T cells. This way 
background proliferation of BALB/C cells to CHO stimulators 
was easily eliminated.
Flow cytometry analysis was performed before the beginning 
of the culture and after 3 days using Cell Quest and a FACScalibur 
(BD). Absolute counts of dividing precursors are achieved using 
Perfect-Count Micrsopheres (Cytognos) as per manufacturer’s 
instructions. An absolute number of successful proliferative 
precursors can thus be obtained, by referring this number to the 
number of seeded cells in the well the frequency is easily calcu-
lated. Frequencies are given as 1 in “n” number of cells obtained 
as mean and standard deviation of the duplicated cultures.
ELISpot Assay for Frequency Calculation
A commercial set of reagents was used (AID), and manufa cturer’s 
instructions were followed. Spots were enumerated with an 
ELISpot reader (AID). Plate was prepared as follows: duplicates 
at five “1/10” dilutions of mixed responder cells (according to the 
mix prepared to have 10–1,000 DO11.10 in the well) in 100 µl of 
medium were seeded. Irradiated and mitomycin-treated stimula-
tor cells (50 ×  104 in 50 µl) were added to all wells. OVA323–339 
peptide at a final concentration of 0.5 mg/ml was also added to 
the necessary wells. Results are given as mean frequency and 
standard deviation calculated from the five dilutions in the format 
of 1 in “n” number of cells. Background spots of IL-2 production 
from negative control well (BALB/C cells and CHO stimulators) 
per dilution were subtracted from experimental IL-2 spots.
FASCIA
A total of 1 ml of PBS diluted (1/10) whole blood was stimulated 
with 50  µM of seven myelin peptides for 7  days at 37°C and 
5% CO2. Non-stimulated and 25  ng/ml PMA plus 250  ng/ml 
Ionomycin-stimulated blood samples were used as negative and 
positive controls, respectively. After 7 days of culture, blood cells 
were stained with anti-CD3-V500 (BD Horizon), anti-CD45-
APC, 7-AAD, and CD4-FITC/CD8-PE (BD Biosciences), and 
after lysis of erythrocytes, samples were acquired with FACS 
FACSVerse (BD Biosciences) and analyzed using the FACS Diva 
software (BD Biosciences). Number of proliferating cells was 
calculated following the protocol and formulas established in the 
Karolinska University Hospital (5).
IFN-γ Production
Allogeneic-Ag-specific responses: labeled PBMCs (105 cells/well) 
were activated with irradiated (600 rad) auto or allo CD3-depleted 
PBMCs (APC) (2 × 105 cells/well) at a responder cells:stimulators 
ratio of 1:1. Alternatively, labeled PBMCs (1 × 105 cells/well) were 
stimulated with auto or allo mDC (104cells/well) at a responder 
cells:stimulators ratio of 10:1 for the indicated time points in 
a final volume of 200  µl of X-VIVO15 medium with 5% HS 
(BioWhittaker-Lonza) and pen/strep (BioWhittaker) in 96-well 
round-bottom plates. Supernatants were harvested after 4 and 
5 days of culture, and levels of IFN-γ were determined by ELISA 
according to the manufacturer’s instructions (BD Biosciences).
Pathogenic Ag-specific responses: labeled PBMCs (2 ×  105 
cells/well) were left inactivated or stimulated with C. albicans 
spores (106/well heat-inactivated spores generously provided by 
Prof. L. Romani, University of Perugia, Italy) or tetanus toxoid 
at 5 µg/ml, or in the presence of total protein extract from a cell 
line infected with V. zoster Virus (5 µg/ml) in a final volume of 
FIgUrE 1 | Road map to establish a dye dilution proliferation assay to monitor antigen-specific T-cell responses. Steps to take into consideration to properly set up 
a dye-based proliferation assay include (1) selection of the appropriate dye and quality control analyses of labeling; (2) defining suitable flow cytometer parameters to 
perform the analyses; (3) outlining the assay by defining the number of cells/wells to be put in culture, selection of responder and stimulatory cells, duration of 
culture, including additional staining for comprehensive analyses; (4) sample acquisition by delineating the gating strategy, i.e., live versus dead cells and number of 
events to acquire; and (5) data analyses.
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200 µl of medium (96-well round-bottom plates). Supernatants 
were harvested after 3, 4, and 5 days of culture and levels of IFN-γ.
statistics
Analysis was performed using the GraphPad Prism 5.0 software. 
The correlation between the different parameters analyzed was 
evaluated by the non-parametric Spearman’s rank correlation 
analysis.
stEPWIsE ProcEDUrEs
Functional in vitro assays to monitor frequency and phenotype 
of Ag-specific T-cell responses using fluorescent dye dilution 
depend on prolonged cell culture and proliferation of Ag-specific 
cells within the cultures. In these assays, responder cells are 
labeled by fluorescent dye and upon Ag-specific stimulation the 
dye is divided equally between daughter cells and the number of 
cell divisions of the proliferating cells can be visualized, allow-
ing the theoretical enumeration of Ag-specific cells (Figure S1 
in Supplementary Material). Here, we outline the critical steps 
required for establishing and analyzing an appropriate dye-based 
proliferation assay in a road map (Figure  1). Several technical 
constrains need to be taken into consideration in the setup of 
the assay, as they will have a definitive impact on the results of 
functional in vitro assays. Although not the focus of this study, 
choices of culture medium, serum lot—if used—and storage of 
reagents are obvious parameters that will affect the results of these 
assays.
An appropriate culture medium that ensures ample nutrient 
availability for the cells throughout the whole period of culture 
should be taken into consideration. Serum remains the preferred 
source of nutrients; however, most cultures are performed with 
5–10% of heat-inactivated fetal calf or bovine serum. If serum 
is to be added to cultures each lot needs to be tested in all of 
the stimulations to be used to ensure the best signal-to-noise 
ratio. We suggest reserving a large amount of the serum lot to 
acquire consistency across a project. Recently, serum-free media 
have become popular (22) and ensure consistency of results 
FIgUrE 2 | Dye-based proliferation assay: dye selection and optimization of the concentration. Freshly isolated CD4+ T cells were labeled with different 
concentrations of CFSE (1, 5, and 10 µM) (A) and VPD-450 (1, 2, and 10 μM) (B), seeded at 1 × 105 cell/well and stimulated with magnetic beads coated with 
anti-CD3 and anti-CD28 antibodies (cell:bead ratio 1:1) for 4 days. The histograms correspond to unlabeled and stimulated cells (blue, auto-fluorescence), labeled 
and stimulated cells (pink) and labeled and unstimulated cells (green). The three cell populations were treated, cultured separately, and mixed before the analysis. 
Prior to the analysis and before mixing the cells, the unstained cells were labeled with anti-CD45 V450 or anti-CD45 FITC antibodies when CFSE or VPD-450 were 
used, respectively, to detect any overlap between stained and unstained cells. CFSE- and VPD-450-labeled and not stimulated cells were significantly smaller than 
labeled and stimulated cells; thus, they were discriminated according to the low values of FSC and SSC parameters. In the upper right corner of each histogram, 
only the proliferation of labeled responders is depicted and % of proliferating cells is presented. For each population only viable (7-AAD−), cells are presented. The 
following parameters are shown: PF = precursor frequency and PI = proliferation index.
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independent of serum lot. Testing of the above-described vari-
ables is beyond the scope of the present work.
Proliferation Dye selection: Defining 
optimal Dye and labeling concentration
Dye-based proliferation assay requires optimization in the 
laboratory where it will be performed, as for most other cell-
based assays. Of specific importance is to optimize PBMC 
labeling with the dye of choice (23). Different proliferation 
dyes can be used, i.e., CFSE, CTV, VPD-450, and eFluor® 
670. The staining intensity of responder cells should be as 
high as possible to obtain a broad analysis window of cell 
division (optimal fluorescence difference between specifically 
labeled cells and autofluorescenceof unlabeled cells). In this 
process of optimization, dye toxicity is an important issue to 
be taken into account. Toxicity of the labeling procedure is 
essential to be avoided by defining the optimal tolerable dye 
concentration, which can be monitored through a live/dead 
staining after culturing of the labeled cells. We recommend 
not only to focus on the induced toxicity, measurable by live/
dead staining, but also to determine the responsiveness of the 
PBMCs to stimulation as one of the quality controls. Polyclonal 
stimulation with anti-CD3 and anti-CD28 mAbs can be used 
to verify the impact of labeling on T-cell proliferation. As an 
alternative, stimulation with mitogens (PHA and PKW), or 
superAgs (SEB), can be used.
An important aspect that should be taken into account dur-
ing optimization of the labeling procedure is the difference in 
dye fluorescence intensity between labeled and unlabeled cells, 
which affects the extent of analysis window. It is therefore clear 
that the choice of dye and labeling concentration for dye-based 
proliferation assays should be the result of a clear validation and 
analysis. In Figure 2, an example of such a dye selection is shown 
in which 3 concentrations of CFSE (1, 5, and 10 µM) and VPD-
450 (1, 2, and 5 µM) were compared to label and analyze isolated 
total CD4+ T cells. After 4-day culture, stimulated labeled cells 
were harvested and analyzed by flow cytometry, using live/dead 
staining and optimization of flow cytometer settings for each dye 
and each dye concentration to allow maximal separation between 
(auto-fluorescent) unlabeled cells and specifically labeled cells. 
The use of 5 and 10  µM CFSE led to higher signal intensities 
(undivided cells reach fifth decade on X-axis, green histograms) 
and better separation of division peaks than 1 µM concentration 
(Figure 2A). However, CFSE concentrations ≥5 µM were associ-
ated with relatively high cell toxicity (25 and 37% dead cells for 5 
and 10 µM concentrations, respectively) as compared with 1 µM 
solution (13% dead cells). In addition, ≥5 µM CFSE concentra-
tions decreased T-cell responsiveness: a lower percentage of 
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responding cells (precursor frequency; PF; pink histograms) was 
observed for cells stained with 5 and 10 µM CFSE solutions than 
for 1 µM CFSE concentration. In addition, high dye concentra-
tions decreased the average number of divisions of responding 
cells (proliferation index; PI). Along the same line, labeling with 
5 µM of VPD-450 also led to higher fluorescence intensity than 
1 and 2 µM solutions of VPD-450 (Figure 2B). Unlike for CFSE, 
cells stained with 1, 2 and 5  µM of VPD-450 showed similar 
viability (13, 18, and 17% of dead cells, respectively), but cell 
responsiveness (% of proliferating cells, PF and PI) was signifi-
cantly lower for 5 µM than for 1 and 2 µM concentrations. When 
results for both dyes were compared, no differences in the dead 
cell frequency (7-AAD+), % of proliferating cells, and PI for 1 µM 
concentrations were observed. However, staining with 1 µM solu-
tion of VPD-450 resulted in a better peak separation than that 
observed for the same concentration of CFSE. Staining with 2 µM 
of VPD-450 further improved peak separation (pink histograms) 
with negligible impact on number of responding cells (PF) and 
PI. Therefore, for this assay setup, VPD-450 would be chosen as 
labeling dye at a concentration of 1 or 2 µM. Described analyses 
underline the importance of a designated assay for the selection 
of the proliferation dye, as a particular dye and/or its applied con-
centration may affect not only cell viability but also the prolifera-
tive responsiveness of the cells. Toxicity and labeling intensity are 
influenced by dye concentration, presence or absence of serum 
or other proteins during the labeling procedure, and the length 
and the temperature of labeling (24). In general, most laboratories 
choose to label PBMCs in a protein-free medium, since the used 
dyes covalently bind to free amines in proteins and hereby labe-
ling of proteins in the medium is prevented. However, Quah and 
Parish (23) optimized the labeling in a protein rich medium by 
using high concentrations of dye and described optimal labeling, 
with low toxicity.
Importantly, every laboratory should perform this selection 
using their procedures, media, reagents and machines. Thus far, 
no specific indications regarding the best dye are available and 
each dye should be carefully tested in each particular setting.
Peaks resolution: Autofluorescence 
versus cell Proliferation
Proper selection of the dye and its labeling concentration together 
with dye-optimized flow cytometer setup enable optimal separa-
tion of positive signal of responding cells (maximally divided 
labeled cells) from autofluorescence of the unlabeled cells 
(Figure  2, blue histograms). Efforts to optimize the signal-to-
noise ratio are crucial to distinguish the separate peaks of dividing 
cells allowing reliable calculation of PFs of the responding cells.
Therefore, to perform optimal proliferation dye-based assays, 
we recommend to test and validate the most appropriate dye and 
its concentration with specific flow cytometer setup (Figure 1).
Assay setup
Definition of the Number of Cells/Wells to Seed
When setting up culture conditions for Ag-specific T-cell enu-
meration, it is very important to use ≥10-fold more cells per 
culture than the expected frequency of responders to reliably 
monitor T-cell responses. Thus, if an Ag-specific response is to 
be measured in naive human individuals, at least 1 million of 
the responder cells need to be seeded, as the frequency of many 
Ag-specific naive T cells is in the order of 1:100,000. In contrast, 
if a subject has already been exposed to a given Ag, it is likely that 
200,000 cells will be enough for detection of a response as the 
frequency of Ag-specific memory T cells is significantly higher 
(10, 25–27).
The threshold of sensitivity of the dye proliferation assay to reli-
ably analyze low frequency T-cell responses is often questioned. 
The sensitivity of the dye proliferation assay was compared to 
ELISpot by using mouse TCR-transgenic CD4+ T  cells specific 
for OVA (DO11.10 cells) (Figure 3). DO11.10 cells were seeded 
at different known concentrations together with CD4+ T  cells 
from naive BALB/c cells, hereby knowing exactly the expected 
frequency of Ag-specific T  cells to be found in the cultures. 
T  cells were stimulated with OVA peptide-loaded CHO cells 
that expressed mouse CD86 (21), and the PFs were determined 
either by IL-2 ELISpot (Figure 3A) or by CFSE proliferation assay 
(Figure 3B). Results of both assays were in good correlation with 
the frequency of Ag-specific T cells in the culture (Figure 3C). 
Notably, at the lower frequencies of Ag-specific T cells (1/104 or 
1/105) the measured frequencies were higher than expected, fall-
ing under the 45° line. Thus, maybe over-estimating the number 
of Ag-specific T cells in these settings. Overall, both methods are 
sensitive enough to reflect differences in frequency of Ag-specific 
T cells between samples.
When dealing with the low frequency of responder cells, we 
recommend calculating the number of cells to seed in culture as 
well as the number of events to be acquired should be calculated 
according to the estimated frequency of the putative Ag-specific 
cells present in the culture (4).
Proper Selection of the Responder, Stimulator Cells 
and Optimal Time Point to Monitor Proliferation
An important issue that has to be taken into consideration 
during optimization of dye-based proliferation assays is the 
proper selection of the responder and stimulator cells to be used 
(Figure 1). Responder cells can be either total PBMCs or purified 
CD4+ or CD8+ T cells; however, the use of total PBMCs could 
be theoretically more informative, since it will allow studying 
the response of different lymphocyte sub-populations (i.e., CD4, 
CD8, effector, naive, and memory T-cell subsets), and analysis of 
activation markers (28). Furthermore, (allo)Ag-specific T  cells 
and dye-based proliferation assay can be combined with the 
intracellular staining for cytokines upon in vitro re-stimulation 
(8, 29, 30) or for transcription factors, such as FOXP3 (31, 32), 
overall obtaining additional information regarding proportions 
of different cell subsets, including Tregs within the Ag-specific 
cell pool present in the culture.
Another important point to take into consideration during 
optimization of the proliferation dye assay is the selection of the 
proper time point to visualize effective proliferation and optimal 
separate division peaks. Examples of how the source of stimula-
tory cells, the purity of the responder cell population and the 
timing may impact the in vitro detection of alloAg-specific T-cell 
responses is provided in the Section “Anticipated Results.”
FIgUrE 3 | Dye-based T-cell proliferation: sensitivity of assay compared to other approaches. CD4+ T cells isolated from the spleen and peripheral lymph nodes of 
BALB/c and DO11.10 mice were labeled independently with CFSE (1 µM). Known numbers of DO11.10 cells were mixed with BALB/C cells and stimulated with 
mitomycin C-treated CHO pulsed with OVA323–339 peptide for 3 days as in Rogers et al. (21). Experimental responding frequencies were determined by (A) IL-2 
enzyme-linked immunospot (ELISpot) or (B) CFSE dilution. (A) Pictures of representative experiment of IL-2 ELISpot wells for each condition tested are shown.  
(B) Representative histograms for each condition tested are depicted. Before acquisition in the flow cytometer cells were labeled with anti-CD4 and anti-KJ126 
mAbs, enabling gating of the DO11.10 CD4+ T cells. (c) Pearson correlation of observed frequencies by ELISpot and CFSE dilution against expected values of three 
independent experiments are presented. In accurate assays, it would be expected, within a tolerable error, that the measurements fall on a 45° line through the 
origin.
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Acquisition setup
To analyze proliferation dye data, a gating strategy focusing on 
living cells and number of acquired events is recommended. Of 
note, in case, the proliferation dye-based assay is used to ana-
lyze alloAg-specific T-cell responses, where allo PBMCs/APCs 
are added as stimulators to the culture, it is very important to 
distinguish between proliferation of responder and stimulator 
cells (both negative for proliferation dye fluorescence). To this 
end, different approaches can be used including labeling of the 
responder and stimulator cells with different dyes or depleting 
CD3+ lymphocytes from stimulator PBMCs.
FIgUrE 4 | Different modes to analyze proliferating cells. Thawed peripheral blood mononuclear cells were labeled with VPD-450 (2 µM) and stimulated with 
Staphylococcal enterotoxin B for 4 (left panel) and 5 (right panel) days. (A) CD8+ T cells were analyzed for the percentage of proliferating cells in total and per division 
peak. The division peaks are numbered 1 through 6. (B) Percentages of proliferating cells, precursor frequency, and the proliferation index have been calculated by 
using the number of events measured in each division peak.
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optimal Parameters for the Analysis of 
Proliferation Dye Data
Results obtained by performing a dye-based proliferation assay 
can be depicted and interpreted in several manners (Figure 1). 
Results of proliferation dye assays are generally presented as 
percentage of cells showing dye dilution (% of proliferating gate, 
Figure S1 in Supplementary Material). The latter is the easiest 
and the most often used parameter to present proliferation data. 
However, this parameter is affected by both the number of cells 
responding to a given stimulus (PF) and the number of divisions 
of dividing cells (PI) and, therefore, gives limited insight in the 
dynamics of cell proliferation and reactive T-cell frequencies. 
Obviously, this result is affected by several parameters, including 
actual percentage of cells responsive to stimulus (also named 
progenitor cells or PF), number of divisions of the dividing cells, 
and occurrence of cell death. Thus, this parameter is good for 
general comparison between different samples but is difficult to 
interpret and may be not sufficient for monitoring Ag-specific 
responses, since it does not directly reflect real percentage of 
Ag-specific T  cells present in culture. Alternatively, results of 
proliferation dye can be depicted as (i) PF (proportion of cells 
with reactivity to a specific Ag or mitogen within the starting 
population), (ii) division index (DI; average number of divi-
sions of all cells, including undivided cells); and (iii) PI (average 
number of cell divisions of responding cells). It is recommended 
to present the PF and PI, since the DI is affected by both the PF 
and the PI. The calculation of these parameters for each dye-
based proliferation culture can be determined by operator or 
by using flow cytometry analysis software (33, 34). In Figure 4, 
an example of different ways to depict proliferation dye data is 
given. Although in both conditions the percentage of proliferat-
ing cells was similar (70.1 vs. 71.4%), the different values for 
the PIs (1.6 vs. 1.9, Table S1 in Supplementary Material) of both 
cultures showed that the cells had not proliferated to the same 
extent in the two conditions. The PFs calculated for the two 
conditions also differed to some extent (PF, 38.4 vs. 30.7%, Table 
S2 in Supplementary Material).
Together, this example underlines the limitations of 
analysis of percentage of proliferating cells and concomitantly 
indicates that the combined use of PI and PF is most informa-
tive to analyze results from proliferation dye-based assays for 
immuno-monitoring. Importantly, percentage of proliferating 
cells is not an informative parameter when it exceeds 60%, 
since the ability to distinguish biological variations becomes 
difficult (34). When monitoring the effect of a tolerizing 
therapy, depicting both PF and PI separately, when possible, 
will give more information regarding the mode of tolerance 
induction. As a drawback, the calculation of PF is not always 
possible due to the lack of visible separate division peaks. This 
possibility can occur when autoAg-specific T-cell proliferation 
is monitored or when alloAg-specific proliferation of cells iso-
lated from patients under immunosuppressive regimens. In the 
latter case, software peak prediction can be used. Nevertheless, 
as shown in this study, in some situations also computational 
prediction cannot be applied. In this case, the only remaining 
option is to present percentage of proliferating wells, as shown 
in the present study. Besides, as for all functional assay, it has 
to be taken into account that the outcomes of the assay will be 
affected by cell death in the culture, and is a reflection of the 
surviving cells.
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ANtIcIPAtED rEsUlts (PItFAlls, 
ArtIFActs, AND troUBlEsHootINg)
To evaluate the mechanisms underlying failure or success of 
tolerogenic therapies in transplantation or autoimmunity, moni-
toring of Ag-specific immune responses is critically important. 
The precise enumeration and phenotypic analysis of Ag-specific 
T  cells remains technically difficult, mainly due to their low 
frequency (26, 27, 35). Therefore, a sensitive, reproducible, and 
reliable method to enumerate and analyze Ag-specific T  cells 
in treated subjects is important. Several approaches have been 
proposed and tested to identify Ag-specific T  cells, including 
proliferative responses and cytokine production profiles. In this 
study, we focus on the use of T-cell proliferation for detection and 
analysis of Ag-specific T cells in PBMCs. We provide evidences 
that a dye-based proliferation assay is as sensitive as other cur-
rently used methods for enumerating low frequency Ag-specific 
T cells.
sensitivity of the Dye Proliferation Assay 
compared to other Approaches
We evaluated the sensitivity of dye-based assays in human 
samples, with unknown frequencies of responder cells in com-
parison with 3H-thymidine incorporation and IFN-γ release. 
We evaluated the cellular response to alloAgs and pathogen-
derived exogenous Ags (C. albicans, tetanus toxoid, and V. 
zoster Virus) (Figures 5 and 6, respectively). For alloAg-specific 
T-cell responses, a comparison of alloAg-specific prolifera-
tion induced by allo CD3-depleted PBMCs (allo APC) or allo 
monocyte-derived mDCs (allo mDC) is shown (Figure 5). As 
negative control, auto APC or mDC (auto mDC) was used. In 
this example, the allo proliferative response induced by allo APC 
was equally good as that induced by allo mDC. CD3-depleted 
PBMCs may be considered as preferred stimulator source, as 
their generation is much less laborious and costly than in vitro 
generated dendritic cell (DC) from allo monocytes, and tend 
to induce less auto background proliferation than allo mDC 
(Figures 5A,B). Comparison of total PBMCs and isolated CD4+ 
T cells as source of responder cells (Figures 5B,C, respectively) 
showed that total PBMCs may be the preferred choice, since 
the proliferative response was comparable to that of purified 
CD4+ T cells, and they are easier and less expensive to obtain. 
Of note, in case of very low expected frequencies of Ag-specific 
T cells, purification of the CD4+ T-cell pool may be advisable to 
increase the relative frequency of the specific T cells in culture 
(Figure  5C). In the case of pathogen-derived Ags, precursors’ 
frequencies were very low (Figure  6) and separate division 
peaks were not visible (Figure S2 in Supplementary Material); 
the precursors’ frequency calculation relied on the software peak 
prediction.
As expected, proliferation in response to alloAgs or pathogen-
derived exogenous Ags can also be detected by 3H-thymidine 
incorporation (Figures 5D and 6C) or IFN-γ release (Figures 5E 
and 6D), although these two read outs did not allow to evaluate 
the proliferation or cytokine secretion specifically by CD4+ or 
CD8+ T cells within PBMCs. Interestingly, while the proliferation 
dye dilution and 3H-thymidine incorporation correlated well 
both in the case of alloAg-specific T-cell responses and the 
responses to pathogen-derived Ags (Figures  5F and 6E), cor-
relation between the proliferation dye dilution and IFN-γ release 
was less evident in the case of alloAg-specific T-cell responses 
but present for pathogen-derived Ag-specific responses (Figure 
S3 in Supplementary Material). From the above experiments, it 
can be concluded that dye proliferation assay is suitable to detect 
T cell specific for alloAgs or pathogen-derived exogenous Ags. 
For optimal readout of alloAg responses 4–5 days of stimulation 
is suitable (Figure  5), while for pathogen-derived exogenous 
Ag responses 7 days of culture is required (Figure 6). The assay 
time is longer compared to other techniques (i.e., H-thymidine 
incorporation or cytokine profiles) (3). This time is mandatory 
for small population of Ag-specific T  cells to reach numbers 
detectable and quantifiable with dye-based assays (4, 36).
The comparison of proliferation data obtained with dye-
based proliferation assay and 3H-thymidine incorporation for 
alloAg- and nominal Ag-specific T-cell response gave good 
concordance. These results are in line with previous reports 
(3, 37–39). However, a less correlation was observed between 
proliferation dye dilution and IFN-γ production, specifically in 
allo mixed lymphocyte reaction. This result may be related to 
NK-cell activation when total allo APC is used as stimulatory 
cells. To avoid this possibility, the use of monocye-derived DCs 
would be recommended. Moreover, it has to be considered that 
in the proposed examples as well as in the present study, correla-
tion is observed when high frequency of Ag-specific T cells is 
present in the peripheral blood and strong antigenic responses 
are analyzed. This is less evident when Ag-specific T  cells are 
less frequent, as in patients with autoimmune disorders, or a less 
immunogenic response is studied (40).
Detection of reactive T cells against autoAgs requires highly 
sensitive techniques due to the low frequency of these auto-
reactive T cells in peripheral blood (26, 27). For this reason, as 
indicated above high numbers of cells (i.e., 1.5 × 105 PBMCs/well) 
in several replicates should be seeded. To test the sensitivity of the 
proliferation dye assay in the detection of autoAg-specific T-cell 
responses, we tested the response of PBMC from multiple sclerosis 
(MS) patients to a mix of seven myelin peptides by comparing the 
proliferation dye (VPD-450), with 3H-thymidine incorporation 
and FASCIA. As depicted in Figure 7A (3), 3H-thymidine incor-
poration is highly sensitive for detecting autoAg-specific T cells, 
since all patients tested exhibited increased proliferation ≥25% of 
analyzed wells compared to the mean of non-stimulated controls 
(Figure 7A). Analysis of proliferation dye dilution indicated that 
separate division peaks were not visible upon autoAg-specific 
stimulation, making it impossible to calculate PF, even with 
the aid of the software peak prediction program. Therefore, as 
alternative the frequency of autoAg-specific T cells was calculated 
as the percentage of positive wells defined by considering repli-
cates showing ≥1.5 stimulation index (SI, % proliferating cells 
stimulated/% proliferating cells non-stimulated). Compared to 
3H-thymidine incorporation, the VPD-450 dilution assay gener-
ated a similar% of positive replicates (≥20% positive wells) in 
three out of four MS patients, while for one patient all replicates 
were positive in the dye-based assay. In parallel, FASCIA was also 
FIgUrE 5 | Dye-based proliferation assay to analyze alloAg-specific T-cell responses. Freshly isolated PBMCs (A,B,D,E) or purified CD4+ T lymphocytes (c) (from 
n = 3 healthy donors) were activated in the presence of either irradiated autologous or irradiated allogeneic CD3-depleted PBMCs (APC) (n = 2 allogenic stimulators) 
at a 1:1 responder: stimulator ratio. Alternatively, cells were stimulated with either autologous or allogenic mature DC (mDC) at a 10:1 responder:stimulator ratio for 
the indicated time points. The proliferative response was evaluated with proliferation dye (efluor-670; 10 µM) (A–c,F) (3), H-thymidine incorporation (D,F), or IFN-γ 
secretion (E). Mean ± SEM of precursor frequencies in the starting population (gated on CD3+ T lymphocytes) (A), means ± SEM of the percentage of proliferating 
CD3+ T cells (B,c), means ± SEM of cpm (D), mean ± SEM of IFN-γ concentration (E) are plotted. Each filled dot represents an independent responder-stimulator 
mismatch. Open dots represent responder-stimulator autologous controls (c). Cutoff for positive response was set as stimulation index (SI) vs. matched autologous 
stimulators >2. Red dots indicate responder-stimulator mismatch with SI <2 (non-responders). (F) Correlation between detection of alloAg-specific response by 
3H-thymidine incorporation and dye-based proliferation was evaluated by Spearman’s rank correlation analysis (non-parametric). The plots show cpm at day 4/5 vs. 
precursor frequency of CD3+ T cells detected at day 6. Each dot represents an independent responder-stimulator (CD3-depleted PBMCs) match (including both 
auto- and allo-stimulators and both PBMC and purified CD4+ T cells as responders) (n = 18 independent determinations for cells derived from three healthy donors). 
The line represents the linear regression; coefficients and p values of the correlation are reported in the graphs. APC: antigen-presenting cells; mDC: monocyte-
derived mature (LPS activated) dendritic cell; cpm: counts per minute; allo: allogeneic; auto: autologous.
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performed by stimulating fresh whole blood from the same MS 
patients with the mix of myelin peptides. The analysis of CD4+ 
blast cells showed a SI ≥1.3 in all samples (Figure 7B), like the SI 
≥1.5 detected in positive auto-reactive wells using VPD-450 dilu-
tion assay. These examples indicate that dye-based proliferation 
assay is sensitive enough to detect T cells specific for a given Ag, 
including blood samples from patients with autoimmune disease 
in whom the frequency of autoAg-specific T cells in peripheral 
blood is generally low.
The latter results are compliant with those of Zafranskaya 
et  al. (41), who compared 3H-thymidine incorporation and 
CFSE-based assay for assessing MOG-reactive T  cells in 
healthy donors, untreated MS patients and IFN-β-treated 
patients. Remarkably, data from MS patients contrast with those 
obtained in type 1 diabetes (T1D) patients. It was demonstrated 
that CFSE-based proliferation assay was more sensitive than 
3H-thymidine incorporation to study auto-Ag-specific reactiv-
ity in T1D patients (3). In this study, all tested patients had a 
FIgUrE 6 | Dye-based proliferation assay to detect pathogen-derived Ag-specific T cells. Freshly isolated PBMCs were left inactivated (white circles, alone) or 
stimulated with Candida albicans spores (solid circles) or tetanus toxoid (triangles), or in the presence of total protein extract from a cell line infected with Varicella 
zoster Virus (squares) for the indicated time points. The proliferative response was evaluated by proliferation dye (efluor-670, 10 µM) of CD4+ T cells (A) and as 
frequency of precursors (B) (3), H-thymidine incorporation (c), or IFN-γ secretion (D). Each dot represents PBMC unstimulated or stimulated with a nominal Ag. 
Cutoff for positive response was set as stimulation index (SI) vs. autologous non-stimulated cells >2. Red symbols indicate donors with SI <2 (non-responders). Ag: 
antigen; cpm: counts per minute. Cells from ≥3 healthy donors were tested for each time point. (E) Correlation between detection of pathogen-specific Ag-specific 
response by 3H-thymidine incorporation and dye-based proliferation was evaluated by Spearman’s rank correlation analysis (non-parametric). The plots show cpm 
at day 5/6 vs. precursor frequency of proliferating CD3+ T cells at day 7. Each dot represents an independent responder PBMC unstimulated or stimulated with 
pathogen-specific Ag (C. albicans or tetanus toxoid or V. zoster Virus) (12 independent experiments were performed with cells derived from three healthy donors). 
The lines represent the linear regression; coefficients and p values of the correlation are reported in the graphs.
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detectable response to glutamic acid decarboxylase (GAD), an 
autoAg in T1D, with CSFE dilution assay, that was revealed only 
in half of the patients by 3H-thymidine incorporation. Moreover, 
Segovia-Gamboa et al. (42) detected GAD- and insulin-specific 
responses with a CFSE-based assay using auto DCs loaded with 
Ag as stimulators for memory CD4+ T cells. We cannot exclude 
that the discrepancy between analyses performed in T1D 
patients and our data depends on the frequency of auto-reactive 
T cells in these patients, duration, and stage of the disease, or 
the immunogenicity of the autoAg. Data obtained with FASCIA 
assays are promising, although the assay is somewhat less sensi-
tive than dye proliferation assay in detecting auto-reactive CD4+ 
T cells. Nevertheless, it can be an alternative in cases PBMC iso-
lation maybe complicated as, for instance, in pediatric patients. 
Although analysis of autoAg-specific responses is challenging, 
we believe that dye-based proliferation assays represent a good 
choice for the enumeration of autoAg-specific T  cells, since 
they allow for measurement of additional phenotypical and cell 
function related parameters critical for a better description of 
auto-reactive T cells and their activation.
FIgUrE 7 | Dye-based proliferation assay to detect autoAg-specific T cells in multiple sclerosis (MS) patients. Freshly isolated PBMC (A) or whole blood (B) from 
four MS patients were stimulated with a mix of seven myelin peptides [myelin oligodendrocyte glycoprotein (MOG) 1–20, MOG35–55, PLP139–154, myelin basic 
protein (MBP) 13–32, MBP83–99, MBP111–129, and MBP146–170] for 7 days. The proliferative response was evaluated by dye-based proliferation (VPD-450, 
1 µM) or 3H-thymidine incorporation (A), or flow cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA) (B). A total of 5 wells 
(VPD-450) or 60 wells (3H-thymidine) were analyzed. The % of autoAg-reactive wells/replicates (wells showing increased 3H-thymidine incorporation compared to the 
mean of non-stimulated wells) (black bars) and the % of autoAg-reactive wells/replicates from VPD-450 dilution assay (wells exhibiting a SI = stimulated wells/
non-stimulated wells ≥1.5) (gray bars) are shown (A). The number of CD4+ blast cells was determined by FASCIA (B).
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In accordance with previous results reported using CFSE-
based assay (43, 44), we showed that dye-based proliferation 
assay is suitable to detect autoAg-specific T cells in peripheral 
blood of MS patients. Moreover, the sensitivity of dye-based 
proliferation assay is comparable to that of 3H-thymidine 
incorporation in detecting auto-reactive T cells in MS patient’s 
PBMC.
coNclUDINg rEMArKs
Dye-based proliferation assays, in contrast to other approaches, 
offer the possibility to retrieve additional information addi-
tional to the overall proliferative response. First, the frequency 
of Ag-specific T-cell precursors in the starting population can be 
determined, which is not the case, for instance, for proliferation 
analyzed by 3H-thymidine incorporation. Furthermore, dye-
based proliferation assays provide insights in the dynamics of 
proliferation and phenotype of the cells at different stages of 
proliferation within a PBMC culture. Tolerizing immunotherapy 
can induce Ag-specific tolerance via several mechanisms: (allo)
Ag-specific T cells can be deleted or become anergic, and this 
will lower the PF (45, 46). Alternatively, the tolerizing therapy 
may cause the (allo)Ag-specific T  cells to respond to a lower 
extent, leading to a restraint on cell division, while not affecting 
PFs. In conclusion, tracking Ag-specific T-cell responses with 
dye dilution represents a valuable tool to monitor tolerance 
induction in human. Strict attention to setup and validation of 
the culture conditions should be given before execution of the 
study while taking into consideration the disease and the type 
of Ag under assessment. We believe that this is the first step to 
harmonize the monitoring of tolerance induction, which will 
enable the comparison of immunological mechanisms respon-
sible for the clinical outcomes of different tolerance-inducing 
studies. In addition, a well-designed and validated dye prolifera-
tion assay can be applied to other therapies aimed at increasing 
Ag-specific T-cell responses such as vaccination and cancer 
immunotherapy.
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